171 related articles for article (PubMed ID: 972005)
1. The absorption metabolism, and excretion of Estracyt (NSC 89199) in patients with prostatic cancer.
Forshell GP; Müntzing J; Ek A; Lindstedt E; Dencker H
Invest Urol; 1976 Sep; 14(2):128-31. PubMed ID: 972005
[TBL] [Abstract][Full Text] [Related]
2. Studies on phenolic steroids in human subjects. XIV. Fate of a nitrogen mustard of estradiol-17beta.
Kirdani RY; Mittelman A; Murphy GP; Sandberg AA
J Clin Endocrinol Metab; 1975 Aug; 41(2):305-18. PubMed ID: 808555
[TBL] [Abstract][Full Text] [Related]
3. [Estracyt (estradiol-nitrogen mustard complex)--estramustine binding protein and its specificity].
Yamanaka H; Imai K; Suzuki T; Yuasa H; Takahashi E
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2106-14. PubMed ID: 6486830
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt"].
Yamanaka H; Shida K
Gan To Kagaku Ryoho; 1984 Mar; 11(3):537-44. PubMed ID: 6422861
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
Andersson SB; Gunnarsson PO; Nilsson T; Forshell GP
Eur J Drug Metab Pharmacokinet; 1981; 6(2):149-54. PubMed ID: 7274309
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients.
Gunnarsson PO; Andersson SB; Johansson SA; Nilsson T; Plym-Forshell G
Eur J Clin Pharmacol; 1984; 26(1):113-9. PubMed ID: 6714283
[TBL] [Abstract][Full Text] [Related]
7. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
Nishio S; Kishimoto T; Maekawa M; Kawakita J; Hayahara N; Yuki K; Morikawa Y; Yasumoto R; Kato Y; Funai K
Hinyokika Kiyo; 1986 Nov; 32(11):1763-70. PubMed ID: 3825823
[TBL] [Abstract][Full Text] [Related]
8. Treatment of oral estramustine phosphate (Estracyt) in prostatic carcinoma: influences on lipid and carbohydrate metabolism.
Gustafson A; Persson B; Tisell LE; Wiklund O; Ohlson R
Invest Urol; 1977 Nov; 15(3):220-4. PubMed ID: 591268
[TBL] [Abstract][Full Text] [Related]
9. Partial characterization and "quantitation" of a human prostatic estramustine-binding protein.
Björk P; Forsgren B; Gustafsson JA; Pousette A; Högberg B
Cancer Res; 1982 May; 42(5):1935-42. PubMed ID: 7066904
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt).
Gunnarsson PO; Forshell GP; Fritjofsson A; Norlén BJ
Scand J Urol Nephrol; 1981; 15(3):201-5. PubMed ID: 7323739
[TBL] [Abstract][Full Text] [Related]
11. Estramustine phosphate: metabolic aspects related to its action in prostatic cancer.
Kadohama N; Kirdani RY; Murphy GP; Sandberg AA
J Urol; 1978 Feb; 119(2):234-9. PubMed ID: 633484
[TBL] [Abstract][Full Text] [Related]
12. Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt).
Vahlensieck W; Wegner G
Scand J Urol Nephrol Suppl; 1980; 55():147-9. PubMed ID: 6938018
[TBL] [Abstract][Full Text] [Related]
13. [Estracyt treatment in prostatic neoplasms].
Sander S
Tidsskr Nor Laegeforen; 1976 Jan; 96(1):27-8. PubMed ID: 1257949
[No Abstract] [Full Text] [Related]
14. Incorporation of 3H-thymidine and 14C-amino acids into the ventral prostate after in vivo treatment with estradiol-3N-BIS(2-chloroethyl)carbamate-17 beta-phosphate (Estracyt) and its estrogen and cytostatic parts.
Hoisaeter PA
Invest Urol; 1976 Sep; 14(2):85-92. PubMed ID: 972011
[TBL] [Abstract][Full Text] [Related]
15. [The phase IV studies with Estracyt in prostatic cancer].
Ohhori T; Kubo T; Akasaka T; Funyu T; Yagihashi Y; Kudo T; Tsuchida S; Harada T; Sasaki S; Orikasa S
Hinyokika Kiyo; 1988 Aug; 34(8):1493-502. PubMed ID: 3057833
[TBL] [Abstract][Full Text] [Related]
16. Metabolic parameters of Estracyt pertinent to its effects in prostatic cancer.
Sandberg AA
Urology; 1984 Jun; 23(6 Suppl):11-21. PubMed ID: 6375075
[No Abstract] [Full Text] [Related]
17. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
Kalland T; Haukaas S
Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
[TBL] [Abstract][Full Text] [Related]
18. Estramustine. Metabolic pattern and possible mechanisms for its action in prostate cancer.
Kadohama N; Kirdani RY; Madajewicz S; Murphy GP; Sandberg AA
N Y State J Med; 1979 Jun; 79(7):1005-9. PubMed ID: 287893
[No Abstract] [Full Text] [Related]
19. Autoradiographic studies of 3H-estramustine in the rat ventral prostate.
Appelgren LE; Forsgren B; Gustafsson JA; Pousette A; Högberg B
Acta Pharmacol Toxicol (Copenh); 1978 Nov; 43(5):368-74. PubMed ID: 726901
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of estramustine phosphate disodium (Estracyt) on prostatic cancer--results of long-term therapy for 38 patients with prostatic cancer].
Asakawa M; Wada S; Hayahara N; Yayumoto R; Kishimoto T; Maekawa M; Morikawa Y; Kawakita J; Umeda M; Horii A
Hinyokika Kiyo; 1990 Nov; 36(11):1361-9. PubMed ID: 2288316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
